Novo Nordisks patents on semaglutide extend through 2032, allowing monopoly pricing without competition
Synthetic analogs mimic its active sequence by adding modifications that resist this enzymatic degradation
Current prescribing information includes warnings related to elevated IGF-1, glucose intolerance, fluid retention, malignancy risk, hypersensitivity, and injection-site reactions. A complete safety discussion belongs in a separate article, but these limitations are essential when interpreting potential benefits
USA 98 , 1030810313 (2001)
PCOS not only significantly reduces female fertility, but is also strongly associated with multiple metabolic syndromes, cardiovascular disease, and type 2 diabetes [3]